Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 9:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 880 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Surgery Control Clear all
Terminated Phase 4 Interventional Results available

Steroid Administration for Articular Fractures of the Elbow (SAFE Trial)

NCT04738318
View directory record Official record
Conditions
Elbow Fracture
Interventions
Glucocorticoids, Saline
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 29, 2023 · Synced Oct 30, 2026, 9:25 AM EDT
Completed Phase 3 Interventional

Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3002

NCT02336698
View directory record Official record
Conditions
Osteoarthritis, Pain
Interventions
Placebo, Fulranumab 1 mg, Fulranumab 3 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
26
States / cities
Phoenix, Arizona • Costa Mesa, California • Laguna Hills, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2017 · Synced Oct 30, 2026, 9:25 AM EDT
Active, not recruiting Phase 2 Interventional

Phase II Study to Evaluate Efficacy and Safety of AMP Peptide PL-5 in Mild Infections of Diabetic Foot Ulcers

NCT06189638
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
Antimicrobial Peptide PL-5 Topical Spray and Placebo
Drug
Lead sponsor
Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Vista, California • Miami, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 30, 2026, 9:25 AM EDT
Completed Phase 2Phase 3 Interventional Results available

XG005 for Pain Control in Subjects Undergoing Bunionectomy

NCT06017999
View directory record Official record
Conditions
Acute Pain
Interventions
XG005 tablet, Placebo tablet
Drug
Lead sponsor
Xgene Pharmaceutical Group
Industry
Eligibility
18 Years to 80 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
8
States / cities
Phoenix, Arizona • San Diego, California • Hialeah, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Oct 30, 2026, 9:25 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of EXPAREL for Prolonged Postsurgical Analgesia in Subjects Undergoing Third Molar Extraction

NCT02517905
View directory record Official record
Conditions
Dental Pain
Interventions
Bupivacaine liposome, Placebo
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Oct 30, 2026, 9:25 AM EDT
Completed Phase 2 Interventional

Study of Acetaminophen (ACE) in Post-operative Dental Pain

NCT02320708
View directory record Official record
Conditions
Dental Pain
Interventions
Acetaminophen (ACE) (1000 mg), Commercial ACE (1000 mg), Commercial Ibuprofen (IBU) (400 mg), Placebo
Drug
Lead sponsor
Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.
Industry
Eligibility
17 Years to 50 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 3, 2021 · Synced Oct 30, 2026, 9:25 AM EDT
Completed Phase 3 Interventional Results available

Gabapentin for Post-Operative Pain Control and Narcotic Reduction in Scrotal Surgery

NCT04230980
View directory record Official record
Conditions
Non-obstructive Azoospermia
Interventions
Gabapentin, Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older · Male only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Oct 30, 2026, 9:25 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of IV Diclofenac (DIC075V) for Pain After Abdominal or Pelvic Surgery

NCT00448110
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Intravenous Diclofenac (DIC075V), Intravenous Ketorolac, placebo
Drug
Lead sponsor
Javelin Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
14
States / cities
Birmingham, Alabama • Florence, Alabama • Montgomery, Alabama + 11 more
Source: ClinicalTrials.gov public record
Updated May 22, 2009 · Synced Oct 30, 2026, 9:25 AM EDT
Completed Not applicable Interventional

Study Exploring the Effect of Music on Pain After Ventral Hernia Surgery

NCT05374096
View directory record Official record
Conditions
Postoperative Pain, Acute, Ventral Hernia, Hernia Abdominal Wall, Surgery, Anxiety
Interventions
Patient-Chosen Music, Placebo
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 21, 2023 · Synced Oct 30, 2026, 9:25 AM EDT
Recruiting Phase 2 Interventional

Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial

NCT06022822
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Placebo Administration, Urolithin A Supplement
Procedure · Drug · Dietary Supplement
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
5
States / cities
Los Angeles, California • Chicago, Illinois • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 30, 2026, 9:25 AM EDT
Completed Phase 3 Interventional Results available

Accelerating Gastrointestinal Recovery

NCT01704651
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
Alvimopan, Placebo
Drug
Lead sponsor
Jamie N. Bakkum-Gamez
Other
Eligibility
18 Years and older · Female only
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 24, 2016 · Synced Oct 30, 2026, 9:25 AM EDT
Withdrawn Phase 2 Interventional

Whether Proton Pump Inhibitors, Administered Prior to or After Surgery, Can Reduce the Incidence and/or Severity of Difficulty Swallowing Foods and/or Liquids,Following Anterior Cervical Surgery

NCT03488147
View directory record Official record
Conditions
Dysphagia, GERD, Degenerative Joint Disease
Interventions
Esomeprazole, Placebo Oral Tablet
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 30, 2026, 9:25 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Vismodegib With Surgery in Participants With Previously Untreated Basal Cell Carcinoma

NCT01898598
View directory record Official record
Conditions
Basal Cell Carcinoma
Interventions
Placebo, Vismodegib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
21
States / cities
Scottsdale, Arizona • Beverly Hills, California • La Jolla, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Oct 30, 2026, 9:25 AM EDT
Completed Phase 3 Interventional Results available

Placebo Controlled Clinical Trial of the Postoperative Opioid Sparing Effects of Intraoperative Dexmedetomidine Infusion for Thoracic Surgery

NCT01973452
View directory record Official record
Conditions
Pain
Interventions
Dexmedetomidine, Placebo
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
4
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 30, 2026, 9:25 AM EDT
Recruiting Phase 2 Interventional

A Study of LY4515100 in Participants With Pain Following Third Molar Removal

NCT07511816
View directory record Official record
Conditions
Acute Pain, Molar, Molar, Third, Surgery, Oral
Interventions
LY4515100, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 40 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 30, 2026, 9:25 AM EDT
Completed Phase 2 Interventional

A Study of MELT-300 (Midazolam and Ketamine Sublingual Tablets) for Sedation and Intraoperative Ocular Analgesia in Participants Undergoing Cataract Extraction With Lens Replacement (CELR)

NCT05133518
View directory record Official record
Conditions
Cataract
Interventions
MELT-300, Midazolam alone, Ketamine alone, Placebo
Drug
Lead sponsor
Melt Pharmaceuticals
Industry
Eligibility
55 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Rancho Cordova, California • Jacksonville, Florida • West Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Dec 19, 2022 · Synced Oct 30, 2026, 9:25 AM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients

NCT03663335
View directory record Official record
Conditions
Kidney Transplantation
Interventions
CFZ533 - Cohort 1/Cohort 2, Mycophenolate Mofetil (MMF), Corticosteroids (CS), Tacrolimus, Induction therapy: basiliximab, Induction therapy: rabbit anti-thymocyte globulin (rATG), Maintenance population: EC-MPS, Maintenance population: MMF, Placebo 1 mL
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 30, 2026, 9:25 AM EDT
Completed Phase 2 Interventional Results available

Study of GBT009 for Treatment of Incisional Wounds Following Breast Reconstruction Surgery

NCT01053897
View directory record Official record
Conditions
Scar Formation
Interventions
GBT009, Placebo
Biological
Lead sponsor
Garnet BioTherapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Chicago, Illinois • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 24, 2013 · Synced Oct 30, 2026, 9:25 AM EDT
Completed Not applicable Interventional

Effect of Bacillus Coagulans and Galactomannans on Obese Patients Undergoing Sleeve Gastrectomy

NCT02868489
View directory record Official record
Conditions
Obesity, Quality of Life
Interventions
LactoWise®, Placebo
Dietary Supplement · Other
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Sep 24, 2021 · Synced Oct 30, 2026, 9:25 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Analgesic Effect of IV Administration of Kappa Agonist CR845 For Hysterectomy Surgery

NCT01361568
View directory record Official record
Conditions
Postoperative Pain
Interventions
CR845, Placebo
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
21 Years to 65 Years · Female only
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
18
States / cities
Florence, Alabama • Mobile, Alabama • Montgomery, Alabama + 14 more
Source: ClinicalTrials.gov public record
Updated May 29, 2014 · Synced Oct 30, 2026, 9:25 AM EDT
Withdrawn Phase 4 Interventional

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Relationship Between Intraoperative Intravenous Acetaminophen and Postoperative Opioid Avoidance for Ambulatory Surgical Procedures

NCT01231191
View directory record Official record
Conditions
Postoperative Pain, Intraoperative and Postoperative Opioid Requirements
Interventions
Intravenous acetaminophen, Intravenous placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 8, 2012 · Synced Oct 30, 2026, 9:25 AM EDT
Active, not recruiting Phase 1 Interventional

GDNF Gene Therapy for Multiple System Atrophy

NCT04680065
View directory record Official record
Conditions
Multiple System Atrophy
Interventions
AAV2-GDNF gene therapy, Sham (Placebo) Surgery
Biological · Procedure
Lead sponsor
Brain Neurotherapy Bio, Inc.
Industry
Eligibility
35 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
7
States / cities
Irvine, California • Boca Raton, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 30, 2026, 9:25 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

NCT03969004
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma
Interventions
Cemiplimab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
40
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 30, 2026, 9:25 AM EDT
Completed Phase 2Phase 3 Interventional

A Study Evaluating the Overall Pain Relief and Safety of Intravenous (IV) CR845 in Patients Undergoing Abdominal Surgery

NCT02542384
View directory record Official record
Conditions
Post Abdominal Surgery Pain
Interventions
CR845 IV 1 mcg/kg, CR845 IV 0.5 mcg/kg, Placebo IV
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
21 Years and older
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
23
States / cities
Sheffield, Alabama • New Haven, Connecticut • Bradenton, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated May 31, 2019 · Synced Oct 30, 2026, 9:25 AM EDT